News & Updates

Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region
Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region
04 Nov 2022 byStephen Padilla

Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.

Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region
04 Nov 2022
Extrapulmonary manifestations of telomere syndrome tied to shorter survival in IPF
Extrapulmonary manifestations of telomere syndrome tied to shorter survival in IPF
04 Nov 2022

Patients with idiopathic pulmonary fibrosis (IPF) who have extrapulmonary manifestations of a telomere syndrome show a decreased survival, according to a recent study.

Extrapulmonary manifestations of telomere syndrome tied to shorter survival in IPF
04 Nov 2022
Psychosis: Has perceived public stigma changed in Hong Kong?
Psychosis: Has perceived public stigma changed in Hong Kong?
04 Nov 2022

Perceived public stigma (PPS) towards psychosis has remained static over 9 years in Hong Kong, with different education groups showing unique patterns of changes in PPS and endorsement of medication treatment across the years, researchers from the University of Hong Kong (HKU) have reported.

Psychosis: Has perceived public stigma changed in Hong Kong?
04 Nov 2022
Vebicorvir plus entecavir safe, effective in chronic HBV patients
Vebicorvir plus entecavir safe, effective in chronic HBV patients
03 Nov 2022 byStephen Padilla

The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.

Vebicorvir plus entecavir safe, effective in chronic HBV patients
03 Nov 2022